NVO · Healthcare
NOVO-NORDISK A S
Smart-money confidence
· 1 of 3 sources firing
Weak — few signals
No standout activity across the feeds we track.
Hedge funds
45
Congress
No data
Insiders
No data
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. ·
how the score works
◆ Next steps
Interested in NOVO-NORDISK A S? Here's what to do with it.
◇
Compare with other stocks
Sort 7,111 stocks by confidence, holders, or Congress signal
◈
Backtest the strategy
See how the model has done historically before you commit real money
✉
Get the weekly digest
One email on Sunday · what changed in the model this week
Not financial advice. Bogen Capital surfaces public SEC filings — you decide what to do with them.
Market cap
$227.7B
Industry
Drug Manufacturers - General
Sector
Healthcare
Exchange
NYSE
About NOVO-NORDISK A S
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin…
Who's behind the signal
Every informed buyer we can see on NVO, across all three feeds.
Hedge funds · 8
Tudor Investment (Paul Tudor Jones)
New position
Gotham Asset Mgmt (Greenblatt)
New position
Citadel Advisors
Increased +137%
Millennium Management (Englander)
Increased +6662%
Baillie Gifford & Co
Increased +39%
AQR Capital Management
Increased +14%
+2 more in the full breakdown below ↓
Congress · 0
No congressional trades on record.
Insiders
No significant Form 4 insider activity in the window.
Not a model pick — but on our radar.
NOVO-NORDISK A S isn't in the top-10 model right now, but 8 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
8
Investors
2
New positions
4
Increasing
1
Decreasing
1
Unchanged
Price History
Loading price data...
Return:
High:
Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Trust weight: 1.2×
% of portfolio
0.1%
Position change
NEW
0.1% of Tudor Investment's portfolio
Trust weight: 1.1×
% of portfolio
0.0%
Position change
NEW
0.0% of Gotham Asset Mgmt's portfolio
Trust weight: 1.0×
% of portfolio
0.3%
Position change
+137%
0.3% of Citadel Advisors's portfolio
Trust weight: 1.0×
% of portfolio
0.1%
Position change
+6662%
0.1% of Millennium Management's portfolio
Trust weight: 1.4×
% of portfolio
0.0%
Position change
+39%
0.0% of Baillie Gifford & Co's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
+14%
0.0% of AQR Capital Management's portfolio
Trust weight: 1.4×
% of portfolio
0.9%
Position change
—
0.9% of Markel Group's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
−20%
0.0% of D.E. Shaw & Co's portfolio
Portfolio Allocation
How much of each investor's portfolio is allocated to NOVO-NORDISK A S
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell NOVO-NORDISK A S or any security.
Get the Weekly Update
Every Sunday, we'll send you what Buffett, Dalio, Ackman and 47 other legendary investors are buying — free, straight from their SEC filings.
Free forever · No spam · Unsubscribe anytime